CD4 and cryptococcosis: Finally, the incorporation of the LFA test by the Brazilian Ministry of Health in June 2021 represents an excellent opportunity for cost-effectiveness analysis of screening and preemptive antifungal therapy in large cohorts of HIV-infected patients with CD4 between 100–200 cells/μL, aiming to establish operational and decision-making strategies to reduce the burden of cryptococcosis among us [54].